CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of “Moderate Buy” by Analysts

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) has received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $9.00.

CAMP has been the topic of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of CAMP4 Therapeutics in a report on Monday, December 29th. Leerink Partners raised their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a report on Friday, March 6th.

CAMP4 Therapeutics Trading Down 1.5%

Shares of CAMP traded down $0.07 during mid-day trading on Wednesday, reaching $4.58. The company had a trading volume of 39,079 shares, compared to its average volume of 187,653. The stock has a market cap of $237.79 million, a price-to-earnings ratio of -1.72 and a beta of 0.41. The firm has a fifty day simple moving average of $2.59 and a 200-day simple moving average of $3.59. CAMP4 Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings results on Thursday, March 5th. The Wireless communications provider reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.56). The company had revenue of $0.35 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,298.54% and a negative return on equity of 162.49%. As a group, equities analysts predict that CAMP4 Therapeutics will post -4.99 EPS for the current fiscal year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Large investors have recently modified their holdings of the company. Bridgeway Capital Management LLC purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth about $36,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of CAMP4 Therapeutics in the 4th quarter worth about $61,000. Jefferies Financial Group Inc. purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at about $70,000. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at about $86,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at about $115,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.